NCT06620744Completed
Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin
Source: ClinicalTrials.gov · Last updated 5 Jun 2025
Brief summary (registry, in English)
This prospective device study will examine the feasibility of MCG data collection in a hospital setting using the SandboxAQ MCG device as a potential method to more accurately and quickly quantify cardiac disease of patients with elevated Troponin.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 20 Sept 2024
- Start date
- 21 Sept 2024
- Primary completion date
- 15 Apr 2025
- Lead sponsor
- SB Technology, Inc.
- Diseases
- Coronary artery disease
- NCT number
- NCT06620744
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 21 Sept 2024 to the primary completion date, 15 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active thoracic metal implants
Other
- Present STEMI
- Having an active atrial fibrillation episode as seen on 12-lead ECG
- Clear non-ischemic cause for symptoms (e.g. trauma)
Who the study is looking for
- Received a positive hs-cTnI based on the institutions laboratory normal value ranges (e.g. female ≥14 and male ≥35)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.